AptarGroup, Inc.

AptarGroup, Inc. Earnings Recaps

ATR Consumer Discretionary 3 recaps
Next earnings: February 4, 2027 (estimated) · full calendar
Q3 2026 Nov 2, 2026

Aptar gained 5.0% after earnings, as 5% core sales growth across all three segments and adjusted EPS at the higher end of guidance likely reassured investors. The quarter also showed areas to watch: emergency medicine destocking weighed on Pharma growth, while Beauty’s North American profitability remains below management’s standard.

Key takeaways
  • Core sales grew 5% across all three segments; adjusted EBITDA margin was 21.3%, within the company’s long-term target range.
  • Pharma growth continued to be affected by lower emergency medicine sales, though management cited broad-based demand across end markets.
  • Beauty posted top-line growth, particularly in prestige fragrance and color cosmetics, but management said North American margin performance needs improvement.
  • Closures delivered double-digit core sales growth; management said margins would have been within the long-term target range absent the impact of indexation.
  • Aptar highlighted a broad Pharma development pipeline, including nasal drug programs in Phase III and Phase II, and ophthalmic and inhalation initiatives; many opportunities remain in development and may take time to contribute.
Q2 2026 Aug 3, 2026

Aptar’s shares were essentially unchanged following earnings, reflecting a mixed quarter with modest sales growth across all segments but limited market enthusiasm due to a neutral overall outlook.

Key takeaways
  • All three segments delivered positive sales growth in the quarter, driven by pharma strength and improving operational performance in beauty and closures.
  • Adjusted EPS came in above guidance, helped by better-than-expected pharma segment results, particularly from injectables and prescription therapies.
  • Pharma growth was supported by demand in injectables for biologics, vaccines, and GLP-1 therapies amid rising weight-loss medication usage.
  • Innovation continued with new patent approvals, including Ensorb technology targeting nitrosamine impurities and early-stage programs for inhaled and nasal GLP-1 therapies.
  • Regulatory milestones included approvals of PMDI technologies using next-generation propellants and recognition as an FDA research partner, reinforcing Aptar’s position in inhaled drug delivery.
Q1 2026 May 4, 2026

Shares fell 2.5% following earnings as investors digested a deceleration in emergency medicine dispensing systems, which negatively impacted core sales by 3%, signaling weakness in a key segment despite growth in other areas.

Key takeaways
  • Core sales declined 3% due to anticipated destocking in emergency medicine dispensing systems following exceptional prior growth.
  • Pharma segment showed strength in GLP-1 biologics, systemic nasal drug delivery, nasal decongestants, and ophthalmic dispensing.
  • Consumer dispensing benefited from volume and mix improvements in beauty and closures, though lower resin pricing pressured margins.
  • Several new product approvals and launches broaden growth platforms, including injectables and nasal delivery technologies.
  • Management emphasized disciplined execution and operational resilience amid a mixed operating environment.